ENTRY       D10954                      Drug
NAME        Mirvetuximab soravtansine (USAN/INN);
            Mirvetuximab soravtansine-gynx;
            Elahere (TN)
PRODUCT     ELAHERE (ImmunoGen)
CLASS       Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Product: D10954<US>
EFFICACY    Antineoplastic, Cell growth inhibitor
  DISEASE   Epithelial ovarian cancer (folate receptor alpha positive) [DS:H00027]
            Fallopian tube cancer (folate receptor alpha positive) [DS:H01554]
            Primary peritoneal cancer (folate receptor alpha positive) [DS:H01665]
  TYPE      Antibody-drug conjugate
TARGET      FOLR1 [HSA:2348] [KO:K13649]
            TUBB [HSA:10381 10382 10383 203068 347688 347733 7280 81027 84617] [KO:K07375]
  PATHWAY   hsa01523(2348)  Antifolate resistance
            hsa04144(2348)  Endocytosis
METABOLISM  Enzyme: CYP3A4 [HSA:1576]
INTERACTION  
BRITE       USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Mirvetuximab Soravtansine
                D10954  Mirvetuximab soravtansine (USAN/INN)
            Drug groups [BR:br08330]
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D10954  Mirvetuximab soravtansine
            Target-based classification of drugs [BR:br08310]
             Transporters
              Other transporters
               Others
                FOLR1
                 D10954  Mirvetuximab soravtansine (USAN/INN) &lt;US&gt;
             Not elsewhere classified
              Cellular process
               Cytoskeleton
                TUBB
                 D10954  Mirvetuximab soravtansine (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10954
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10954
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10954
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D10954
DBLINKS     CAS: 1453084-37-1
            PubChem: 350078327
///
